top of page
Sage Group News
The Sage Group Represents VAL401 - A Unique Formulation of Respiridone for Cancer Supportive Care
The Sage Group is working with UK-based ValiRx, which is developing a unique, patented, cancer supportive care product, VAL401, for which...
IPSC-Derived Cardiomyocyte Product to Treat Chronic Heart Failure Patients - Partnering Opportunity
Help Stem Cell Innovations (“HelpTx” or the “Company”; helptx.com.cn) is a Nanjing, China-based stem cell biotechnology company dedicated...
Exhalation Technology Announces Plans for Commercial Launch and Clinical Update on CoronaCheck
Exhalation Technology Announces Plans for Commercial Launch and Clinical Update on CoronaCheck – A Rapid (<5 minutes) Covid-19 Diagnostic...
Zhimeng Biopharma Announces Global Partner Search for its' Development of Chronic Hepatitis B Cure
Shanghai, China and New York, USA, 1 March 2021 – Following a strategic review of its clinical and commercial development options,...
The Sage Group Announces $100M+ Transaction between medac GmbH and Medexus Pharma for Trecondi
The Sage Group Inc. served as exclusive advisor to medac GmbH on this $100M+ transaction. Medexus Pharmaceuticals and medac GmbH enter...
Squarex Announces End of Phase 2 Meeting with FDA for its Cold Sore Prevention Asset
Saint Paul, Minnesota, USA, 19 January 2021 – Squarex Pharma (SQX), a St. Paul, Minnesota, USA-based company, announced updated results...
Exhalation Technology Announces Updated Clinical Trial Data for its Rapid Covid-19 Diagnostic Test
Cambridge, England, 4 January 2021 – Exhalation Technology (ETL), a Cambridge, UK-based company, announced updated results from its...
Exhalation Technology Launch Clinical Trial for CoronaCheck™ – A Rapid Covid-19 Diagnostic Test
Cambridge, England, 2 November 2020 – Exhalation Technology (ETL), a Cambridge, UK-based company, announced the start of a large clinical...
bottom of page